FraAP / Sapience Therap - LARVOL DELTA

Targeted antagonism of the activator protein 1 transcription factor complex results in potent anti-tumor activity in HNSCC models (AACR 2026) - "Further, while FraAP results in significant anti-tumor activity as a monotherapy in HNSCC subcutaneous xenograft models, combination of subpharmacologic FraAP and abemaciclib results in enhanced tumor growth inhibition. In summary, these data support FraAP as a potent peptide antagonist of the AP-1 transcription factor family that warrants further development as a novel therapeutic option for AP-1 driven tumors such as HNSCC."

Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ANXA5 • CCND1 • CDH1 • CDH2 • CDKN1A • FRA1

Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 (PRNewswire) - "Sapience will present clinical and non-clinical results from ST316, a first-in-class antagonist of β-catenin, as well as results from its preclinical Fra1 antagonist peptide (FraAP) program, a first-in-class antagonist of the activator protein 1 (AP-1) complex."

Preclinical • Colorectal Cancer • Squamous Cell Carcinoma of Head and Neck

FraAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in HNSCC models (AACR 2025) - "Further, in a HNSCC subcutaneous xenograft model, administration of FraAP results in significant tumor growth inhibition, demonstrating the anti-cancer potential of targeting the AP-1 complex. In summary, these data support FraAP as a potent peptide antagonist of the AP-1 transcription factor family that warrants further development as a potential therapeutic option for AP-1 driven tumors."

Preclinical • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ANXA5 • CDH1 • CDH2 • FRA1